Kristin Astrom, DO
Family Medicine · Sparks, NVNPI 1982693859
Payments from drug & device makers
Across 362 payments — averaging $17.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- AstraZeneca$833
- GSK$647
- Novo Nordisk$328
- Lilly USA, LLC$325
- Pfizer$313
- plus $2K from 29 others
What the payments were for
- Food & beverage$6,28699%
- Education$361%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 100 | $1,887 |
| AstraZeneca | 48 | $833 |
| GSK | 40 | $647 |
| Novo Nordisk | 18 | $328 |
| Lilly USA, LLC | 22 | $325 |
| Pfizer | 22 | $313 |
| Boehringer Ingelheim | 14 | $231 |
| Merck | 12 | $220 |
| Abbott | 12 | $202 |
| Amgen(2 entities) | 7 | $170 |
| Bayer | 8 | $166 |
| Idorsia Pharmaceuticals US Inc | 8 | $123 |
| Sanofi-aventis U.S. LLC | 8 | $121 |
| Exact Sciences | 5 | $84 |
| Astellas Pharma US Inc | 3 | $84 |
| Corcept Therapeutics | 4 | $64 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $48 |
| Johnson & Johnson | 3 | $46 |
| Biohaven Pharmaceuticals, Inc. | 2 | $43 |
| Esperion Therapeutics, Inc. | 2 | $40 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $38 |
| Eisai Inc. | 2 | $37 |
| Paratek Pharmaceuticals, Inc. | 2 | $33 |
| Tactile Systems Technology Inc | 2 | $31 |
| Sumitomo Pharma America, Inc. | 1 | $26 |
| Actelion Pharmaceuticals US, Inc. | 1 | $24 |
| Medtronic | 1 | $23 |
| Sunovion Pharmaceuticals Inc. | 3 | $23 |
| Hologic Sales And Service, LLC | 1 | $18 |
| Kowa Pharmaceuticals America, Inc. | 1 | $17 |
| Dexcom, Inc. | 1 | $16 |
| Kyowa Kirin, Inc. | 1 | $16 |
| Scilex Pharmaceuticals Inc. | 1 | $15 |
| Vanda Pharmaceuticals Inc. | 1 | $15 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $14 |
How this compares
$6,322 in reported general payments places this provider in the 90th percentile of 902 family medicine providers in Nevada.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 41 | $62,373 |
| EliquisApixaban | 45 | $53,771 |
| JardianceEmpagliflozin | 35 | $44,842 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 22 | $32,812 |
| MounjaroTirzepatide | 14 | $23,625 |
| MyrbetriqMirabegron | 13 | $16,349 |
| FarxigaDapagliflozin Propanediol | 11 | $10,619 |
| Gabapentin | 125 | $3,921 |
| Levothyroxine Sodium | 254 | $3,606 |
| SynthroidLevothyroxine Sodium | 60 | $3,217 |
| Rosuvastatin Calcium | 142 | $3,170 |
| Atorvastatin Calcium | 224 | $2,879 |
| Estradiol | 24 | $2,393 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 75 | $1,995 |
| Bupropion XlBupropion Hcl | 32 | $1,952 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $328 | $62,37341 claims |
| PfizerEliquis | $313 | $53,77145 claims |
| Boehringer IngelheimJardiance | $231 | $44,84235 claims |
| GSKTrelegy Ellipta | $647 | $32,81222 claims |
| Lilly USA, LLCMounjaro | $325 | $23,62514 claims |
| Astellas Pharma US IncMyrbetriq | $84 | $16,34913 claims |
| AstraZenecaFarxiga | $833 | $10,61911 claims |
| AbbVieSynthroid | $1,887 | $3,21760 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 902 family medicine providers in Nevada.
Other family medicine in Sparks
- Sangeeta WagnerSparks$880K
- Ronald HicksSparks$9K
- Rogelio MachucaLas Vegas$3.3M
- Maxine InghamLas Vegas$2.9M
- Elliot ShinLas Vegas$2.1M
- Robert KaplanLas Vegas$1.7M
- Sean SuLas Vegas$1.1M
- Susan ParkReno$1.1M
- Naz WahabLas Vegas$735K
- Carmelo RilleraLas Vegas$531K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.